Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17526
Title: Xp11 translocation renal cell carcinoma paraneoplastic syndrome presenting as cutaneous vasculitis: first reported case of yet another mask.
Austin Authors: Pascoe, Claire;Christidis, Daniel;Clouston, David;Lawrentschuk, Nathan
Affiliation: Department of Urology, Austin Health, Heidelberg, Victoria, Australia
YURO, Young Urology Researchers Organisation, Melbourne, Victoria, Australia
Cancer Surgery, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia
Department of Pathology, Tissue Path, Mount Waverley, Victoria, Australia
Issue Date: 21-Apr-2018
Date: 2018-04-21
Publication information: BMJ Case Reports 2018; 2018: bcr-2017-223423
Abstract: Renal cell carcinoma is historically known as the 'great masquerader' with 40% of patients experiencing a paraneoplastic syndrome. Translocation carcinoma represents one-third of renal cancer in paediatric patients but less than 3% of renal cancers in patients aged 18-45 years where the clinical course is often rapidly terminal. There are less than 10 reported cases of leucoclastic vasculitis associated with clear cell carcinoma reported in the literature and 10 case reports of translocation carcinoma in adults. To our knowledge, we present the first reported case of Xp11 translocation carcinoma presenting as cutaneous vasculitis, as part of a paraneoplastic syndrome, in an adult patient. Our case highlights that renal cell cancers are truly the 'great masquerader' and a rash can be the first sign of renal malignancy.
URI: https://ahro.austin.org.au/austinjspui/handle/1/17526
DOI: 10.1136/bcr-2017-223423
ORCID: 0000-0003-2951-3726
0000-0001-8553-5618
Journal: BMJ Case Reports
PubMed URL: 29680797
Type: Journal Article
Subjects: dermatology
surgical oncology
urological surgery
urology
Appears in Collections:Journal articles

Show full item record

Page view(s)

26
checked on Nov 14, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.